<DOC>
	<DOC>NCT01162681</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, safety and tolerability of three different doses of A-623 administered in addition to standard therapy in subjects with active SLE disease</brief_summary>
	<brief_title>PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Diagnosis of SLE by American College of Rheumatology guidelines. On stable SLE treatment Active SLE disease Serologically active 18 years of age or older Receiving stable doses of prednisone between 7.5 mg and 40 mg per day Severe active vasculitis, active central nervous system lupus, active lupus nephritis, uncontrolled hypertension, or uncontrolled diabetes. Known to be positive for HIV and/or positive at the screening visit for hepatitis B, or hepatitis C. Liver disease. Anemia, neutropenia, or thrombocytopenia. Malignancy within past 5 years Active infection requiring hospitalization or treatment with parenteral antibiotics within the past 60 days or history of repeated herpetic viral infections. History of active tuberculosis or a history of tuberculosis infection. Participation in the active treatment arm of any Phase 2 or Phase 3 clinical trial for a molecule that primarily targets the B cell pathway in the past 18 months. Prior administration of any B cell depleting therapy in the past 18 months. Pregnant or nursing History of congenital immunodeficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>SLE</keyword>
	<keyword>Lupus</keyword>
	<keyword>Lupus Erythematosus, Systemic</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>A-623</keyword>
	<keyword>Blisibimod</keyword>
</DOC>